RO7568282 for Early Symptomatic Alzheimer's Disease
Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease
- Age
- 50 – 90
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 450 (estimated)
- Sponsor
- Hoffmann-La Roche · Industry
This trial is looking for people in the early stages of Alzheimer's disease to compare a new treatment called RO7568282 with a placebo. Participants will need to meet certain health criteria and have a study partner to help them.
You may be able to join if
- I have early Alzheimer's disease confirmed by a medical test.
- I have mild cognitive impairment or mild dementia due to Alzheimer's.
- I can swallow whole capsules.
- My body mass index is between 18 and 34.
- I have a study partner who can assist me.
You may not be able to join if
- I have another condition that affects my thinking.
- I have had serious heart problems in the last year.
- I have dangerous blood pressure that is hard to control.
- I have had serious problems with blood vessels in my brain.
- I have significant brain abnormalities seen on an MRI.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThis study aims to compare the effects of RO7568282 versus a placebo in people in the early stages of Alzheimer's disease (AD).
Loading trial locations…
Reference Study ID Number: BP46554 https://forpatients.roche.com/ No attachments to email below.
888-662-6728
global-roche-genentech-trials@gene.com
CONTACT
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
CONTACT